

[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PopSet](#)[Taxonomy](#)[OMIM](#)[Bc](#)Search

for

Go

Clear

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)

Display

Abstract

Sort

Save

Text

Clip Add

Order

[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[PubMed Services](#)[Journal Browser](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: Oncology (Huntingt) 2000 Dec;14(12 Suppl 13):29-32[Related Articles, Books, LinkOut](#)

Irinotecan and thalidomide in metastatic colorectal cancer.

Govindarajan R.

Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m² every 21 days and thalidomide (Thalomid) at 400 mg/d. Of the 15 patients, 11 were in a pilot study and 4 were in an ongoing phase II protocol. There were 12 men and 3 women, with a median age of 56 years (range: 29 to 79 years). Patients were treated with a median of three cycles (range: one to eight cycles). The four patients enrolled in the formal protocol were not evaluable for response at the time of this report. Of the 11 patients in the pilot study, 10 were evaluable for response; there were two complete responses, two partial responses, and six progressions. Investigators noted a remarkable absence of grade 3/4 gastrointestinal toxicities, and concluded that further testing of the complete response and toxicity profile of the irinotecan/thalidomide regimen was warranted.

Publication Types:

- Clinical Trial
- Clinical Trial, Phase II

PMID: 11204671 [PubMed - indexed for MEDLINE]

Display

Abstract

Sort

Save

Text

Clip Add

Order

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)